Best Compounded GLP-1 Telehealth Providers of 2026
Compounded GLP-1s — semaglutide and tirzepatide mixed by 503A or 503B compounding pharmacies — remain the most affordable on-ramp to the GLP-1 category in 2026. The FDA's 2024 ruling closed the official tirzepatide shortage, which means compounding now operates under the personalisation exception (a clinician must document a clinical justification, such as dose customisation, the addition of B12, or a documented intolerance to an inactive ingredient in the brand-name product). Pricing, pharmacy licensure, and formulation breadth still vary widely between providers. We compared every clinic in our network that ships a compounded GLP-1, and ranked the ones with the strongest combination of pharmacy transparency, real clinical oversight, and price predictability.
Rankings combine clinical formulary depth, pricing transparency, and shipping reliability — weighted equally and reviewed quarterly. Read the full methodology →
The Ranking
Personalized clinical weight loss with state-licensed pharmacy fulfillment and an unusually low program entry price.
Flat-rate compounded GLP-1s plus brand-name Wegovy and Zepbound, with all dosages priced the same.
Broad-catalog telehealth covering hair, skin, weight loss, and sexual health, with free shipping and follow-ups bundled in.
Hormone optimisation platform with real biomarker testing and physician-guided protocols, for men and women.
Affordable subscription telehealth with one of the largest compounded formularies in the industry.
Full-spectrum GLP-1 program with both compounded and brand-name access plus unlimited provider check-ins.
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Publicly traded telehealth giant with weight-loss, ED, and hair-loss programs under one roof.
Yucca Health
Provider-guided care from US-licensed pharmacies, covering GLP-1, NAD+, and recovery-focused peptides.
Embody
Flexible, medically guided compounded GLP-1 weight loss with transparent monthly pricing.
Affordable men's health clinic specialised in TRT and weight loss with transparent pricing.
Personalised, physician-endorsed longevity and weight-loss therapies, fully online.
Methodology
Each provider was scored on four axes — (1) compounded formulary breadth (injectable, oral, sublingual, lozenge, microdose), (2) price-per-mg transparency at every dose tier, (3) pharmacy disclosure (503A vs 503B, named partner, USP-797 sterility documentation), and (4) clinical oversight depth (real video visits vs async-only, prescriber state coverage, follow-up cadence). Brand-name access was not weighted — this list is specifically about compounded GLP-1 quality, not Wegovy or Zepbound availability.
What the Studies Actually Show
Compounded GLP-1s contain the same active ingredient as Wegovy / Ozempic (semaglutide) or Zepbound / Mounjaro (tirzepatide). They have not themselves been studied in randomised trials; efficacy is inferred from the trials of the underlying API, summarised below.
| Endpoint | Finding |
|---|---|
| Mean weight loss (STEP 1, 68 weeks, 2.4 mg)1 | −14.9% body weight vs −2.4% placebo in adults with overweight/obesity without diabetes |
| Cardiovascular outcomes (SELECT, ~40 months)2 | 20% relative risk reduction in major adverse cardiovascular events (MACE) in adults with established CV disease and overweight/obesity |
| GI side effects (FDA prescribing information)3 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥10%, constipation ≥10%; most cases mild–moderate and dose-dependent |
| Boxed warning3 | Risk of thyroid C-cell tumors observed in rodent studies; contraindicated in personal/family history of MTC or MEN 2 |
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)6 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)7 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)8 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
Frequently Asked Questions
Are compounded GLP-1s legal in 2026?
Yes — compounded GLP-1s remain legal under the FDA's personalisation exception. After the 2024 ruling that ended the official tirzepatide and semaglutide shortages, compounding is permitted only when a licensed clinician documents a clinical justification, such as a customised dose, the addition of vitamin B12, or a documented allergy to an inactive ingredient in the brand-name product. Reputable providers include this documentation in their intake.
What's the difference between 503A and 503B compounding pharmacies?
503A pharmacies compound on a per-prescription basis for an individual patient and are state-licensed. 503B outsourcing facilities are FDA-registered, follow CGMP standards, and can produce larger batches — generally considered the higher-tier sterility option for injectables. Some providers (Eden, Henry Meds, Mochi) use 503B partners and disclose it. Always ask which pharmacy fulfils your script.
Is compounded semaglutide as effective as Wegovy?
Compounded semaglutide uses the same active ingredient as Wegovy and Ozempic. Real-world outcomes are broadly comparable when sourced from a licensed compounding pharmacy with verified API. The variable is sterility and formulation consistency — which is why pharmacy licensure (503A vs 503B) matters. Compounded products are not FDA-approved as finished drugs.
What's the cheapest compounded GLP-1 telehealth provider in 2026?
Within our network, Wellorithm, Mochi, and Eden consistently lead on price-per-mg, with starting plans from $149 to $199 per month including provider visits. The actual cheapest option depends on your starting dose — some clinics charge flat rates regardless of dose (TMates, Wellorithm), while others surcharge as you titrate up.
Do compounded GLP-1s come with B12?
Some do, some don't. Compounded semaglutide-with-B12 and tirzepatide-with-B12 are common formulations because the addition of B12 is one of the documented clinical justifications under the personalisation exception. Hims, Eden, Henry Meds, and Mochi explicitly offer B12-bundled formulations.
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- FDA Prescribing Information — Wegovy (semaglutide) · WEGOVY (semaglutide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SUSTAIN program — ADA scientific summary · Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 clinical trials. Diabetes Obes Metab 2019;21(7):1601–1613.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- FDA Prescribing Information — Zepbound (tirzepatide) · ZEPBOUND (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.